Experimental Virus-Antibody combo tested for tough skin cancers
Disease control
Terminated
This early-phase study tested a combination of two drugs—a virus-based therapy (talimogene laherparepvec) and an antibody (panitumumab)—in 5 people with advanced skin squamous cell carcinoma that had spread or come back. The goal was to see if the combination was safe and could s…
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 26, 2026 08:19 UTC